| Nordquist, Luke |
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer |
|
|
| Recruiting | 4 | 700 | Europe, Canada, US, RoW | AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617 | Novartis Pharmaceuticals | Prostate Cancer | 07/33 | 07/33 | | |
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
|
|
| Terminated | 3 | 105 | US | VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga | Veru Inc. | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 05/23 | 05/23 | | |
| Active, not recruiting | 3 | 439 | Europe, US | 177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide | Curium US LLC | Metastasis From Malignant Tumor of Prostate | 08/24 | 02/29 | | |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
DORA, NCT03574571: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer |
|
|
| Recruiting | 3 | 738 | Europe, US, RoW | Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223 | Memorial Sloan Kettering Cancer Center, Bayer | Prostate Cancer | 06/26 | 06/26 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 3 | 804 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
| Active, not recruiting | 3 | 1100 | Europe, Canada, US, RoW | Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy | University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium | Prostate Cancer | 01/28 | 07/28 | | |
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
|
|
| Recruiting | 2/3 | 60 | US | FPI-2265, Ac225-PSMA I&T | Fusion Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 01/31 | | |
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC |
|
|
| Completed | 2 | 61 | US | GT0918, proxalutamide, androgen receptor antagonist | Suzhou Kintor Pharmaceutical Inc, | Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 03/22 | 09/22 | | |
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer |
|
|
| Completed | 2 | 53 | US | 64Cu-SAR-BBN | Clarity Pharmaceuticals Ltd | Biochemical Recurrence of Malignant Neoplasm of Prostate | 05/24 | 05/24 | | |
TATCIST, NCT05219500: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (). |
|
|
| Recruiting | 2 | 115 | US | FPI-2265, Ac225-PSMA I&T | Fusion Pharmaceuticals Inc. | Metastatic Castration Resistant Prostate Cancer | 12/24 | 12/25 | | |
CONVERGE-01, NCT06549465: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 2 | 47 | US | In-111 rosopatamab tetraxetan, 45 KBq/kg Ac-225 rosopatamab tetraxetan, 55 KBq/kg Ac-225 rosopatamab tetraxetan, 60 KBq/kg Ac-225 rosopatamab tetraxetan | Convergent Therapeutics | PSMA PET-Positive Castration-Resistant Prostate Cancer | 12/25 | 04/27 | | |
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial) |
|
|
| Active, not recruiting | 2 | 234 | US | Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide | Dana-Farber Cancer Institute, Bayer, Decipher Biosciences | Prostate Cancer | 03/25 | 03/28 | | |
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care | Novartis Pharmaceuticals | Prostatic Neoplasm | 10/27 | 12/28 | | |
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer |
|
|
| Recruiting | 2 | 219 | US | Enoblituzumab, MGA271, Standard of Care | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics | Prostate Cancer | 03/29 | 03/29 | | |
NCT05286840: 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer |
|
|
| Not yet recruiting | 1/2 | 150 | US | 64Cu-SAR-bisPSMA | Luke Nordquist, MD, Clarity Pharmaceuticals | Prostate Cancer | 03/23 | 09/23 | | |
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer |
|
|
| Completed | 1/2 | 52 | US | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Biochemical Recurrence of Malignant Neoplasm of Prostate | 08/23 | 08/23 | | |
COMBAT, NCT05633160: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 |
|
|
| Recruiting | 1/2 | 38 | US | 64Cu-SAR-BBN, 67Cu-SAR-BBN | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | 05/26 | 05/26 | | |
| Recruiting | 1/2 | 144 | US | ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto | OncoC4, Inc., Prostate Cancer Clinical Trials Consortium | Metastatic Castration-resistant Prostate Cancer | 06/26 | 06/27 | | |
NCT05617040: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer |
|
|
| Active, not recruiting | 1/2 | 144 | US | ChAdOx1-PCAQ, MVA-PCAQ | Barinthus Biotherapeutics | Prostate Cancer | 08/26 | 04/27 | | |
SECURE, NCT04868604: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) |
|
|
| Recruiting | 1/2 | 44 | US | 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | 09/26 | 09/26 | | |
| Terminated | 1/2 | 21 | Europe, US | ONCT-534, GTx-534, UT-34 | Oncternal Therapeutics, Inc | Metastatic Castration-resistant Prostate Cancer | 09/24 | 09/24 | | |
NCT05773703: Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer |
|
|
| Completed | 1 | 23 | US | PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122 | Ratio Therapeutics, Inc. | Prostate Cancer | 12/23 | 12/23 | | |
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 12/24 | 04/25 | | |
NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors |
|
|
| Recruiting | 1 | 30 | US | ²¹²Pb-DOTAM-GRPR1 | Orano Med LLC | Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma | 08/24 | 01/25 | | |
NCT05605522: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours |
|
|
| Recruiting | 1 | 42 | US, RoW | [225]-FPI-2059, [111In]-FPI-2058 | Fusion Pharmaceuticals Inc. | Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer | 06/25 | 09/25 | | |
| Lemon, Stephen |
| No trials found |
